Secretory uterine corpus endometrioid adenocarcinoma

Summary

Secretory uterine corpus endometrioid adenocarcinoma (MONDO:0004174) is a disease. A subtype of endometrium adenocarcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	secretory uterine corpus endometrioid adenocarcinoma
Mondo ID	MONDO:0004174
DOID	DOID:7289
NCIT	C27839
UMLS	C1266057
MedGen	690079
Is cancer (heuristic)	no

Also known as: endometrial endometrioid adenocarcinoma, secretory variant · secretory uterine corpus endometrioid adenocarcinoma

Disease family

This is a subtype of endometrium adenocarcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › reproductive system cancer › female reproductive organ cancer › uterine cancer › uterine carcinoma › endometrial carcinoma › endometrium adenocarcinoma › secretory uterine corpus endometrioid adenocarcinoma

Related subtypes (8): endometrial mucinous adenocarcinoma, villoglandular endometrial endometrioid adenocarcinoma, oxyphilic endometrial endometrioid adenocarcinoma, mucin-rich endometrial endometrioid adenocarcinoma, endometrial endometrioid adenocarcinoma with spindled epithelial cells, endometrial mixed adenocarcinoma, endometrial clear cell adenocarcinoma, ovarian endometrioid adenocarcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.